Boukovala Myrto, Spetsieris Nicholas, Efstathiou Eleni
Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center , Houston, TX, USA.
Expert Opin Pharmacother. 2020 Sep;21(13):1537-1546. doi: 10.1080/14656566.2020.1770726. Epub 2020 Jun 16.
Novel androgen signaling inhibitors are currently standard of care in the treatment of patients with prostate cancer. Second-generation androgen receptor antagonists have demonstrated efficacy in earlier disease settings, fulfilling an unmet need in the treatment of patients with advanced prostate cancer.
The present article focuses on the development and establishment of apalutamide among the available treatment options for prostate cancer. A literature search was performed in Pubmed/Medline for past studies and reviews of the drug. Ongoing clinical trials were also examined in the Clinicaltrials.gov online database.
Apalutamide has demonstrated benefit for patients with non-metastatic castration resistant and metastatic hormone naive prostate cancer. It is an efficacious, tolerable, and convenient oral agent, thus a valuable addition in the armamentarium of prostate cancer therapeutics for both non-metastatic castrate resistant and metastatic hormone naïve prostate cancer. Ongoing trials are investigating the drug as monotherapy and in combinations in other disease settings. Results are expected to further expand the drug's indications and shape the future landscape of prostate cancer therapy.
新型雄激素信号抑制剂目前是前列腺癌患者治疗的标准护理方法。第二代雄激素受体拮抗剂已在早期疾病环境中显示出疗效，满足了晚期前列腺癌患者治疗中未满足的需求。
本文重点关注阿帕他胺在前列腺癌现有治疗选择中的研发与确立。在Pubmed/Medline中进行文献检索，以查找该药物过去的研究和综述。还在Clinicaltrials.gov在线数据库中审查了正在进行的临床试验。
阿帕他胺已证明对非转移性去势抵抗性和转移性激素初治前列腺癌患者有益。它是一种有效、可耐受且方便的口服药物，因此对于非转移性去势抵抗性和转移性激素初治前列腺癌而言，是前列腺癌治疗药物库中的一个有价值补充。正在进行的试验正在研究该药物作为单一疗法以及在其他疾病环境中的联合应用。预计结果将进一步扩大该药物的适应症，并塑造前列腺癌治疗的未来格局。
